EW Nutrition is accelerating its expansion strategy after a transformative 2026 that included major acquisitions.
Speaking with Expana at EuroTier 2026 in Hanover, Germany this week, Daniele Marzin, Director of Product Management at EW Nutrition, outlined the company’s ambitious plans to leverage recent deals while investing heavily in production capacity and research capabilities.
The company completed two significant acquisitions in 2026 that are reshaping its portfolio. EW Group acquired Olmix in August 2026, gaining access to the company’s proprietary algae-based technologies for natural animal and plant care solutions. Additionally, EW Nutrition announced in February 2026 plans to fully own Brazilian feed additive leader GRASP by the end of 2029 through a phased acquisition approach.
Regarding Olmix’s integration, Marzin emphasized the strategic fit of the acquisition. “Olmix was acquired by EW Group for its unique algae technology. Indeed Olmix has developed a full seaweed processing chain from collection to final innovative products,”, and this fits perfectly with EW Nutrition’s vision of securing future animal protein production in a sustainable way, using natural-based solutions,” she said.
The GRASP acquisition marks a logical evolution of a relationship spanning 15 years. EW Nutrition has maintained a joint venture with GRASP since 2011. “GRASP is one of the leaders in the Brazilian market in the feed additive business, pioneer in plant extracts based products and more recently developing also on yeasts derivatives,” Marzin explained.
She said that the company is strategically deploying GRASP’s established market presence to introduce EW Nutrition innovations across Brazil, such as a new heat-resistant xylanase product, while GRASP products are simultaneously rolling out across EW Nutrition’s global operations.
Managing product overlap across a rapidly expanding portfolio presents challenges for any company undertaking multiple acquisitions simultaneously. However, Marzin downplayed concerns about duplication. “With GRASP as part of EW Nutrition and Olmix as part of EW Group, we are just seeing what any large company usually experiences: There are different markets out there, different customer segments, different customers. There are no conflicts in managing a wide portfolio, there are only opportunities for customers,” she said.
Looking forward to 2027, capital deployment will focus on geographic regions expected to experience the most significant growth in animal protein production, Marzin said.
EW Nutrition plans investments in production capacity at its plant in Constanti, Spain, which is currently operating at full capacity. The company will also continue expanding manufacturing in India and Latin America while maintaining investment in China.
Research and development receives equal priority. The company is expanding its main research facility in Cologne, Germany, establishing new competence platforms focused on enzymes, antioxidants, antimicrobial phytogenic screening, and microbiome analysis.
Finally, despite an active 2026 acquisition environment, Marzin indicated that M&A remains on the radar. “M&A is still being monitored even after this very busy 2026 and we continue to look at potential targets, mainly to grow the portfolio. The vision is clear: we need to continue to invest,” she said.
According to Marzin, the company’s expansion strategy reflects confidence in the commitment of parent company, the family-owned EW Group. “We are very fortunate to be part of EW Group, a family-owned holding company with a strong belief in the future of animal protein. Where other companies divest and zigzag, we keep expanding in both portfolio and geographical range, and we continue to invest in the future,” Marzin said.
Written by Simon Duke